Table 1.
Scheme of experiment
| Group | No. of animals | Group's characteristics | Treatment scheme |
|---|---|---|---|
| A1 | 30 | No treatmentMortality control | – |
| A2 | 40 | No treatmentTaking blood samples | – |
| B1 | 30 | Treatment with rmIFN-γMortality control | Days 4–16 after infection,daily, intraperitoneally,1·7 × 103 IU/mouse |
| B2 | 40 | Treatment with rmIFN-γTaking blood samples | Days 4–16 after infection,daily, intraperitoneally,1·7 × 103 IU/mouse |
| C1 | 30 | Treatment with rmTNFα.Mortality control | Days 4–16 after infection,daily, intraperitoneally,5·4 × 104 RU/mouse |
| C2 | 40 | Treatment with rmTNFα.Taking blood samples | Days 4–16 after infection,daily, intraperitoneally,5·4 × 104 RU/mouse |
| D1 | 30 | Treatment with combination of rmTNFα and rmIFN-γ.Mortality control | Days 4–16 after infection,daily, intraperitoneally,rmIFN-γ 0·85 × 103 IU/mousermTNFα 2·7 × 104 RU/mouse |
| D2 | 40 | Treatment with combination of rmTNFα and rmIFN-γ.Taking blood samples | Days 4–16 after infection,daily, intraperitoneally,rmIFN-γ 0·85 × 103 IU/mousermTNFα 2·7 × 104 RU/mouse |
BALB/c mice were infected with EV, strain K-1, at a dose of 5 LD50.